GLP-1 Medication Guide

The patient notebook

A little clarity, one question at a time.

Open the source shelf ↗

Additional researched option

Boston Medical Group Review

Compounded GLP-1 telehealth offers

Boston Medical Group markets weight care as SlimFitRx on its main website and offers a separate online GLP-1 pathway through its prescription site. The latter advertises compounded semaglutide from $99 and tirzepatide from $149 per month, while another heading on the same page says plans start at $190. Those figures need to be reconciled in the actual quote. [Source]

A useful first appointment would answer three questions: what exact medicine is proposed, what the full purchase costs and who provides the follow-up. This public-source review follows those questions through the offer and policies. We did not complete an intake, obtain a prescription or verify a checkout price for a particular patient.

Write down the product and the complete price

The main SlimFitRx page discusses semaglutide and tirzepatide alongside lifestyle changes. The prescription-site cards identify compounded GLP-1 and GLP-1/GIP options, list four weeks of medication, and describe ongoing provider care, syringes, alcohol pads and platform access. The page also says consultation, medication and shipping are included. [Source]

The $99 and $149 cards are starting amounts, not verified invoices. They appear alongside the $190 program headline. The page says the monthly rate depends on the prescribed medication and does not rise with dose changes, but the reviewed public selection page did not resolve the amount due, the chosen term or a promotion’s renewal price. [Source]

Ask the provider to put the medication, preparation, supply period, charge today and next payment on one written summary. Four weeks of supply and a calendar-month billing cycle need not coincide. Do not convert the lowest advertised amount into a guaranteed total for every prescription or plan.

Understand the platform and the people providing care

The prescription-site terms describe Boston Medical Group and third-party services. Its public footer says the platform connects patients with independent licensed healthcare providers and does not itself dispense medication or make clinical decisions. We did not independently verify an individual prescriber, the precise contracting medical entity or the pharmacy assigned to a GLP-1 order. [Source]

The returns page lists a Boston Medical Group/Manifest Pharmacy return address. A return address alone does not establish that this pharmacy dispenses every medication or every compounded GLP-1 preparation. Obtain the actual pharmacy name and contact details on the prescription and dispensing label. [Source]

The FAQ says the service does not accept insurance and describes access across multiple states. It does not establish a verified nationwide weight-loss service list. A clinician’s license and the proposed pharmacy’s ability to serve the patient’s state still matter. [Source]

The billing and cancellation statements

The FAQ says medication is billed when shipped, based on the selected treatment plan. It also says customers can reorder or cancel through their account and will be contacted before medication is refilled and billed. We have not tested the account controls, an advance notice or the timing of an actual payment. [Source]

The Returns & Refund Policy says prescription products cannot be returned after dispensing. It describes sales as final once payment has been charged and the package has been given to the carrier. It allows account changes or subscription cancellation before shipment, but does not provide a complete GLP-1-specific refund calculation for a charged, approved or dispensed order that has not shipped. [Source]

Request the exact renewal cutoff and ask whether canceling the subscription also stops an existing order. The policy’s shipment-based finality statement should not be turned into an unconditional promise that every earlier stage is refundable. Keep the accepted order terms and confirmation of any cancellation.

Delivery questions to bring to the pharmacy

For damaged or missing prescription deliveries, the policy directs customers to patient care. Its lost-package section describes working with the carrier and reshipping. The same general page says the service does not ship refrigerated products; that statement needs clarification for the particular GLP-1 prescription, rather than being treated as proof that temperature is unimportant. [Source]

The offer describes a clinical approval step within 24 hours, followed by pharmacy fulfillment. The FAQ similarly describes approximate clinician feedback within a day. These are company timing claims, not measured approval, delivery or clinical-message response times. A question about medication handling belongs with the actual dispensing pharmacy. [Source]

Before starting, ask how to contact the prescriber about symptoms, how refill decisions are made and where a shipping complaint should go. The administrative contact and the professional responsible for clinical advice may be different people.

Keep outcome claims in their proper category

The main weight-loss page presents substantial average weight-loss figures for semaglutide and tirzepatide. It does not provide a clinic-specific patient study in the reviewed material establishing those results for SlimFitRx customers or a particular compounded preparation. This review does not award clinical scores or treat promotional averages as a personal prediction. [Source]

FDA does not approve compounded medicines or review them before marketing for safety, effectiveness and quality. An ingredient name shared with a branded drug does not establish an interchangeable product. Ask why an approved option cannot meet the individual medical need and what evidence supports the proposed preparation. [Source]

The appointment preparation note helps organize these questions. The Lemonaid Health review shows another billing model, with membership and medication separated. Compare the written arrangements after a clinician has considered treatment suitability.

Sources for this note

New provider sources checked October 15, 2026. Earlier material retains its original source history. Provider sources describe advertised offers; they do not independently establish quality of care.

  1. Boston Medical Group: SlimFitRx programProvider public information; checked October 15, 2026
  2. Boston Medical Group: Current GLP-1 offerProvider public information; checked October 15, 2026
  3. Boston Medical Group: Returns and refundsProvider public information; checked October 15, 2026
  4. Boston Medical Group: Service FAQProvider public information; checked October 15, 2026
  5. Boston Medical Group: Telehealth-site termsProvider public information; checked October 15, 2026
  6. FDA — concerns with unapproved GLP-1 drugsRegulator guidance · Checked 2026-10-21